首页 > 最新文献

Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan最新文献

英文 中文
[Elucidation of a Novel Protective Function of AADAC Against Drug-induced Liver Injury through Ferroptosis Suppression]. [通过抑制铁下垂阐明AADAC对药物性肝损伤的新保护功能]。
IF 0.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2026-01-01 DOI: 10.1248/yakushi.25-00145-4
Tatsuki Fukami

Drug-induced liver injury (DILI) remains a major cause of drug withdrawal from the market, and safety concerns in clinical settings. Reactive metabolites, primarily produced by cytochrome P450 enzymes, are known to induce oxidative stress and hepatotoxicity through covalent binding to macromolecules and the generation of reactive oxygen species. Recent evidence suggests that ferroptosis, an iron-dependent form of lipid peroxidation-mediated cell death, is involved in DILI triggered by compounds such as carbon tetrachloride (CCl4) and acetaminophen (APAP). Arylacetamide deacetylase (AADAC), a hepatic hydrolase previously recognized for its role in drug metabolism, has recently been implicated in tumor suppression and ROS regulation in cancer cells. In this study, our group explored whether AADAC exerts a protective effect against ferroptosis-associated liver injury. Using Aadac knockout (KO) mice, we demonstrated that CCl4, APAP, and amodiaquine induced more severe liver damage in the absence of Aadac, with elevated ferrous (Fe2+) levels, lipid peroxidation, and oxidative stress. We identified that Aadac interacts with ceruloplasmin, a ferroxidase that converts Fe2+ to ferric (Fe3+), thereby limiting ferroptosis. Notably, this function of Aadac was independent of its enzymatic activity. Furthermore, human AADAC overexpression in Huh-7 cells similarly reduced intracellular Fe2+ levels and conferred protection against CCl4-induced cytotoxicity in a ceruloplasmin-dependent manner. These findings reveal a novel, non-catalytic role for AADAC in iron homeostasis and ferroptosis suppression, suggesting its clinical significance in DILI susceptibility and therapy.

药物性肝损伤(DILI)仍然是药物退出市场的主要原因,也是临床环境中安全性问题的主要原因。活性代谢物主要由细胞色素P450酶产生,已知通过与大分子的共价结合和活性氧的产生诱导氧化应激和肝毒性。最近的证据表明,铁死亡是一种铁依赖形式的脂质过氧化介导的细胞死亡,参与由四氯化碳(CCl4)和对乙酰氨基酚(APAP)等化合物引发的DILI。芳基乙酰胺脱乙酰酶(Arylacetamide deacetylase, AADAC)是一种肝脏水解酶,以前被认为在药物代谢中起作用,最近被认为与肿瘤抑制和肿瘤细胞中的ROS调节有关。在这项研究中,我们小组探讨了AADAC是否对铁中毒相关的肝损伤有保护作用。在Aadac敲除(KO)小鼠中,我们证明了CCl4、APAP和amodiaquine在缺乏Aadac的情况下会引起更严重的肝损伤,导致亚铁(Fe2+)水平升高、脂质过氧化和氧化应激。我们发现Aadac与铜蓝蛋白相互作用,铜蓝蛋白是一种铁氧化酶,可将铁2+转化为铁(Fe3+),从而限制铁凋亡。值得注意的是,Aadac的这种功能是独立于它的酶活性的。此外,人类AADAC在Huh-7细胞中的过表达同样降低了细胞内Fe2+水平,并以铜蓝蛋白依赖的方式保护细胞免受ccl4诱导的细胞毒性。这些发现揭示了AADAC在铁稳态和铁下沉抑制中的一种新的非催化作用,提示其在DILI易感性和治疗中的临床意义。
{"title":"[Elucidation of a Novel Protective Function of AADAC Against Drug-induced Liver Injury through Ferroptosis Suppression].","authors":"Tatsuki Fukami","doi":"10.1248/yakushi.25-00145-4","DOIUrl":"https://doi.org/10.1248/yakushi.25-00145-4","url":null,"abstract":"<p><p>Drug-induced liver injury (DILI) remains a major cause of drug withdrawal from the market, and safety concerns in clinical settings. Reactive metabolites, primarily produced by cytochrome P450 enzymes, are known to induce oxidative stress and hepatotoxicity through covalent binding to macromolecules and the generation of reactive oxygen species. Recent evidence suggests that ferroptosis, an iron-dependent form of lipid peroxidation-mediated cell death, is involved in DILI triggered by compounds such as carbon tetrachloride (CCl<sub>4</sub>) and acetaminophen (APAP). Arylacetamide deacetylase (AADAC), a hepatic hydrolase previously recognized for its role in drug metabolism, has recently been implicated in tumor suppression and ROS regulation in cancer cells. In this study, our group explored whether AADAC exerts a protective effect against ferroptosis-associated liver injury. Using Aadac knockout (KO) mice, we demonstrated that CCl<sub>4</sub>, APAP, and amodiaquine induced more severe liver damage in the absence of Aadac, with elevated ferrous (Fe<sup>2+</sup>) levels, lipid peroxidation, and oxidative stress. We identified that Aadac interacts with ceruloplasmin, a ferroxidase that converts Fe<sup>2+</sup> to ferric (Fe<sup>3+</sup>), thereby limiting ferroptosis. Notably, this function of Aadac was independent of its enzymatic activity. Furthermore, human AADAC overexpression in Huh-7 cells similarly reduced intracellular Fe<sup>2+</sup> levels and conferred protection against CCl<sub>4</sub>-induced cytotoxicity in a ceruloplasmin-dependent manner. These findings reveal a novel, non-catalytic role for AADAC in iron homeostasis and ferroptosis suppression, suggesting its clinical significance in DILI susceptibility and therapy.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"146 2","pages":"123-129"},"PeriodicalIF":0.2,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"146100767","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Effect of Kamishoyosan on Primary Dysmenorrhea Pain]. [神食杂山对原发性痛经疼痛的影响]。
IF 0.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-11-01 Epub Date: 2025-09-05 DOI: 10.1248/yakushi.24-00219
Yayoi Aoki, Taiki Shimoyama, Seiwa Michihara, Shigeki Chiba

Dysmenorrhea refers to pathological symptoms that occur in association with menstruation during the menstrual period. Treatment options for dysmenorrhea include nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose estrogen-progestin combination pills. However, some patients do not respond to these treatments, and long-term use can lead to adverse reactions, raising additional problems. To overcome these issues, Kampo (traditional Japanese herbal) medicines are often used, with prescriptions based on Kampo medicine diagnoses. In this study, we investigated the analgesic effects of Kamishoyosan, a Kampo medicine frequently used to treat this disease, using a mouse primary dysmenorrhea (PD) model. Since Kamishoyosan is typically administered over a long term in clinical settings, we also evaluated its effects on PD after single-dose or repeated long-term administration. Oxytocin administration to continuously estradiol-treated mice significantly increased the number of writhing responses (an index of pain), uterine tissue level of prostaglandin F2α (PGF2α), and calcium ion (Ca2+) level, while uterine blood flow significantly decreased. In contrast, repeated administration of Kamishoyosan decreased the number of writhing responses. The uterine tissue PGF2α and Ca2+ levels reduced after single-dose administration at a high dose and regardless of dosage after repeated administration. Uterine blood flow was improved by single-dose administration regardless of dosage. These results showed that continuous administration of Kamishoyosan exerted analgesic effects on PD symptoms even at non-high doses. Furthermore, Kamishoyosan may reduce PD-related pain by acting on uterine contraction factor (including PG)-producing pathways and uterine blood flow.

痛经是指在月经期间发生的与月经有关的病理症状。痛经的治疗选择包括非甾体抗炎药(NSAIDs)和低剂量的雌激素-黄体酮联合药片。然而,一些患者对这些治疗没有反应,长期使用可能导致不良反应,引发其他问题。为了克服这些问题,经常使用汉方(传统的日本草药)药物,处方基于汉方医学诊断。在本研究中,我们用小鼠原发性痛经(PD)模型研究了Kamishoyosan的镇痛作用,Kamishoyosan是一种经常用于治疗这种疾病的柬埔寨药。由于Kamishoyosan通常在临床环境中长期使用,我们也评估了单剂量或重复长期给药对PD的影响。连续给予雌二醇后,小鼠扭体反应次数(疼痛指数)、子宫组织中前列腺素F2α (PGF2α)水平、钙离子(Ca2+)水平显著升高,子宫血流量显著减少。与此相反,反复服用神生草多糖则减少了扭动反应的次数。高剂量单次给药后子宫组织PGF2α和Ca2+水平降低,重复给药后不论给药剂量。不论剂量大小,单次给药均可改善子宫血流量。这些结果表明,即使在非高剂量的情况下,持续给药神蛇草糖对PD症状也有镇痛作用。此外,神蛇草多糖可能通过作用于子宫收缩因子(包括PG)产生途径和子宫血流来减轻pd相关疼痛。
{"title":"[Effect of Kamishoyosan on Primary Dysmenorrhea Pain].","authors":"Yayoi Aoki, Taiki Shimoyama, Seiwa Michihara, Shigeki Chiba","doi":"10.1248/yakushi.24-00219","DOIUrl":"10.1248/yakushi.24-00219","url":null,"abstract":"<p><p>Dysmenorrhea refers to pathological symptoms that occur in association with menstruation during the menstrual period. Treatment options for dysmenorrhea include nonsteroidal anti-inflammatory drugs (NSAIDs) and low-dose estrogen-progestin combination pills. However, some patients do not respond to these treatments, and long-term use can lead to adverse reactions, raising additional problems. To overcome these issues, Kampo (traditional Japanese herbal) medicines are often used, with prescriptions based on Kampo medicine diagnoses. In this study, we investigated the analgesic effects of Kamishoyosan, a Kampo medicine frequently used to treat this disease, using a mouse primary dysmenorrhea (PD) model. Since Kamishoyosan is typically administered over a long term in clinical settings, we also evaluated its effects on PD after single-dose or repeated long-term administration. Oxytocin administration to continuously estradiol-treated mice significantly increased the number of writhing responses (an index of pain), uterine tissue level of prostaglandin F2α (PGF2α), and calcium ion (Ca<sup>2+</sup>) level, while uterine blood flow significantly decreased. In contrast, repeated administration of Kamishoyosan decreased the number of writhing responses. The uterine tissue PGF2α and Ca<sup>2+</sup> levels reduced after single-dose administration at a high dose and regardless of dosage after repeated administration. Uterine blood flow was improved by single-dose administration regardless of dosage. These results showed that continuous administration of Kamishoyosan exerted analgesic effects on PD symptoms even at non-high doses. Furthermore, Kamishoyosan may reduce PD-related pain by acting on uterine contraction factor (including PG)-producing pathways and uterine blood flow.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":" ","pages":"899-906"},"PeriodicalIF":0.2,"publicationDate":"2025-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145016300","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevention of Serious Adverse Drug Reactions and Economic Effects Through Community Pharmacists' Inquiries, Home Care, and Medication Follow-up: From The Japanese Nationwide Pharmacy Collaboration Survey in 2023. 社区药师问诊、家庭护理及用药随访预防严重药物不良反应及经济效应——来自2023年日本全国药房合作调查
IF 0.2 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-08-01 Epub Date: 2025-06-09 DOI: 10.1248/yakushi.25-00010
Shu Sekiya, Rei Tanaka, Hisashi Iijima, Yoshio Nakano, Satoru Miyazaki, Atsushi Toyomi, Hajime Hashiba, Masanori Nagatsu, Yoshiaki Shikamura

Community pharmacists play a vital role in delivering person-oriented services, such as addressing prescription inquiries, providing home care services, and conducting medication follow-ups. Despite their significance, no nationwide surveys have assessed the efficacy of these pharmaceutical activities. Therefore, this study aimed to collect information on these three pharmacist tasks and investigate their effectiveness in preventing serious adverse drug reactions and reducing medical costs. Ten percent of insurance pharmacies in each prefecture were randomly selected to participate in the survey. Data were collected on basic pharmacy information, prescription inquiries, home care services, and medication follow-up, which spanned from 12 June to 18 June 2023. Of the 561 pharmacies pre-registered for the study, valid responses were obtained from 433 pharmacies (77.2%). The reported cases included 3064 prescription inquiries, 765 home care services, and 326 medication follow-ups. Prescription inquiries prevented serious adverse drug reactions in 122 cases, home care services in 209 cases, and medication follow-ups in 13 cases. The cost reductions associated with these activities were ¥28291790, ¥58285600, and ¥2544950, respectively, resulting in a total cost reduction of ¥89122340. The annual cost reduction was ¥33229078321.7, assuming a severity rate of 6.7%. The estimated annual reduction in medical costs specifically attributed to prescription inquiries was ¥8732177830. This study indicates that pharmacists prevent adverse drug reactions and contribute to the safety of drug treatment through prescription inquiries, home care services, and medication follow-up. These tasks reduced annual medical costs by approximately ¥42 billion, highlighting the economic and healthcare benefits of community pharmacy services.

社区药剂师在提供以人为本的服务方面发挥着至关重要的作用,例如解决处方询问,提供家庭护理服务以及进行药物随访。尽管具有重要意义,但尚未进行全国性调查评估这些药物活动的功效。因此,本研究旨在收集这三种药师任务的信息,探讨其在预防严重药物不良反应和降低医疗费用方面的有效性。每个县随机抽取10%的保险药店参与调查。收集了2023年6月12日至6月18日期间的基本药房信息、处方查询、家庭护理服务和用药随访数据。在561家预先注册的药店中,433家(77.2%)获得了有效回复。报告病例包括处方咨询3,064例,家庭护理服务765例,药物随访326例。处方询问预防严重药物不良反应122例,家庭护理服务预防209例,药物随访预防13例。与这些活动相关的成本削减额分别为28,291,790日元、58,285,600日元和2,544,950日元,总成本减少额为89,122,340日元。假设严重率为6.7%,年度成本降低为33,229,078,321.7元。估计每年因处方询问而减少的医疗费用为8 732 177 830日元。本研究显示药师透过处方询问、居家照护服务及用药随访,预防药物不良反应,促进药物治疗安全。这些任务每年减少了大约420亿日元的医疗费用,突出了社区药房服务的经济和保健效益。
{"title":"Prevention of Serious Adverse Drug Reactions and Economic Effects Through Community Pharmacists' Inquiries, Home Care, and Medication Follow-up: From The Japanese Nationwide Pharmacy Collaboration Survey in 2023.","authors":"Shu Sekiya, Rei Tanaka, Hisashi Iijima, Yoshio Nakano, Satoru Miyazaki, Atsushi Toyomi, Hajime Hashiba, Masanori Nagatsu, Yoshiaki Shikamura","doi":"10.1248/yakushi.25-00010","DOIUrl":"10.1248/yakushi.25-00010","url":null,"abstract":"<p><p>Community pharmacists play a vital role in delivering person-oriented services, such as addressing prescription inquiries, providing home care services, and conducting medication follow-ups. Despite their significance, no nationwide surveys have assessed the efficacy of these pharmaceutical activities. Therefore, this study aimed to collect information on these three pharmacist tasks and investigate their effectiveness in preventing serious adverse drug reactions and reducing medical costs. Ten percent of insurance pharmacies in each prefecture were randomly selected to participate in the survey. Data were collected on basic pharmacy information, prescription inquiries, home care services, and medication follow-up, which spanned from 12 June to 18 June 2023. Of the 561 pharmacies pre-registered for the study, valid responses were obtained from 433 pharmacies (77.2%). The reported cases included 3064 prescription inquiries, 765 home care services, and 326 medication follow-ups. Prescription inquiries prevented serious adverse drug reactions in 122 cases, home care services in 209 cases, and medication follow-ups in 13 cases. The cost reductions associated with these activities were ¥28291790, ¥58285600, and ¥2544950, respectively, resulting in a total cost reduction of ¥89122340. The annual cost reduction was ¥33229078321.7, assuming a severity rate of 6.7%. The estimated annual reduction in medical costs specifically attributed to prescription inquiries was ¥8732177830. This study indicates that pharmacists prevent adverse drug reactions and contribute to the safety of drug treatment through prescription inquiries, home care services, and medication follow-up. These tasks reduced annual medical costs by approximately ¥42 billion, highlighting the economic and healthcare benefits of community pharmacy services.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":" ","pages":"707-722"},"PeriodicalIF":0.2,"publicationDate":"2025-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144249895","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Toward Establishing a Japanese Drug Discovery Ecosystem: The Role of Startups and a Model Tailored to Japan]. [建立日本药物开发生态系统:初创企业的作用和适合日本的模式]。
IF 0.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-07-01 Epub Date: 2025-05-09 DOI: 10.1248/yakushi.25-00015
Ryo Okuyama

Establishing a robust drug discovery ecosystem is seen as a key priority for enhancing Japan's drug discovery capabilities. Globally, startups play a significant role in advancing drug discovery. The author's research demonstrated that startups have recently expanded their role to late-entry drug discovery, the area where large pharmaceutical companies traditionally had strength, while maintaining their contribution to first-in-target drug discovery. Despite the growing importance of startups, Japan has faced challenges in fostering successful drug discovery startups, falling particularly behind in leveraging modality technologies. The development of promising startups requires the establishment of a robust startup ecosystem, as seen in the U.S. and certain European countries. Japan's ecosystem for supporting drug discovery startups remains fragile due to factors such as low entrepreneurial activity, limited labor mobility, and insufficient investment capital. The author's research has revealed that in Japan's unlisted drug discovery startups, "being a corporate spin-off" and "having a leader in research and development with prior experience in corporate R&D" positively impact the startup's valuation and total funding amounts. In Japan, large pharmaceutical companies still account for the majority of new drug discoveries, with a wealth of promising drug discovery seeds and experienced R&D talent accumulated within these corporations. Facilitating the creation of corporate spin-offs that utilize unexploited seeds within large companies and promoting the transfer of corporate talent to startups could strengthen Japan's drug discovery ecosystem. This paper will also explore potential policy measures to encourage these developments.

建立一个强大的药物发现生态系统被视为提高日本药物发现能力的关键优先事项。在全球范围内,初创公司在推动药物发现方面发挥着重要作用。作者的研究表明,创业公司最近扩大了他们在后期药物发现领域的作用,这是大型制药公司传统上有优势的领域,同时保持了他们对首发药物发现的贡献。尽管初创企业的重要性日益增加,但日本在培育成功的药物发现初创企业方面面临着挑战,特别是在利用模式技术方面落后。有前途的创业公司的发展需要建立一个强大的创业生态系统,就像美国和某些欧洲国家所看到的那样。由于创业活动低、劳动力流动性有限和投资资本不足等因素,日本支持药物研发初创企业的生态系统仍然脆弱。作者的研究表明,在日本未上市的药物研发初创企业中,“作为企业分拆”和“拥有具有企业研发经验的研发负责人”对初创企业的估值和总融资金额产生了积极影响。在日本,大型制药公司仍然占新药发现的大部分,这些公司积累了大量有前途的药物发现种子和经验丰富的研发人才。促进企业衍生产品的创建,利用大公司内部未开发的种子,并促进企业人才向初创公司的转移,可以加强日本的药物发现生态系统。本文还将探讨鼓励这些发展的潜在政策措施。
{"title":"[Toward Establishing a Japanese Drug Discovery Ecosystem: The Role of Startups and a Model Tailored to Japan].","authors":"Ryo Okuyama","doi":"10.1248/yakushi.25-00015","DOIUrl":"10.1248/yakushi.25-00015","url":null,"abstract":"<p><p>Establishing a robust drug discovery ecosystem is seen as a key priority for enhancing Japan's drug discovery capabilities. Globally, startups play a significant role in advancing drug discovery. The author's research demonstrated that startups have recently expanded their role to late-entry drug discovery, the area where large pharmaceutical companies traditionally had strength, while maintaining their contribution to first-in-target drug discovery. Despite the growing importance of startups, Japan has faced challenges in fostering successful drug discovery startups, falling particularly behind in leveraging modality technologies. The development of promising startups requires the establishment of a robust startup ecosystem, as seen in the U.S. and certain European countries. Japan's ecosystem for supporting drug discovery startups remains fragile due to factors such as low entrepreneurial activity, limited labor mobility, and insufficient investment capital. The author's research has revealed that in Japan's unlisted drug discovery startups, \"being a corporate spin-off\" and \"having a leader in research and development with prior experience in corporate R&D\" positively impact the startup's valuation and total funding amounts. In Japan, large pharmaceutical companies still account for the majority of new drug discoveries, with a wealth of promising drug discovery seeds and experienced R&D talent accumulated within these corporations. Facilitating the creation of corporate spin-offs that utilize unexploited seeds within large companies and promoting the transfer of corporate talent to startups could strengthen Japan's drug discovery ecosystem. This paper will also explore potential policy measures to encourage these developments.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":" ","pages":"617-628"},"PeriodicalIF":0.3,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144064580","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Changes in the Serum Calcium Level and Renal Function After Switching from Alfacalcidol to Eldecalcitol]. [从阿法骨化醇切换到依地骨化醇后血清钙水平和肾功能的变化]。
IF 0.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-04-01 Epub Date: 2025-03-28 DOI: 10.1248/yakushi.24-00160
Hiroko Nagae, Haruka Nagai-Nakamura, Kouhei Noda, Daiki Hagiwara, Susumu Kaneshige, Hidetoshi Kamimura

Active vitamin D3 (VDRAs) can cause drug-induced hypercalcemia and acute renal failure. Eldecalcitol (ELD), a VDRA, promotes bone formation more strongly than other VDRAs, such as alfacalcidol (ALF), but whether or not ELD affects serum calcium (Ca) levels and renal function more significantly than other VDRAs is unclear. In Japan, the supply of ALF was temporarily stopped in 2021, and patients at Fukuoka University Hospital who were taking ALF were either switched to ELD or discontinued ALF. We retrospectively investigated how these prescription changes affected serum Ca levels and renal function. Sixty-seven adult patients who were admitted to our hospital for at least 5 d between September 2021 and March 2022 and were taking ALF at the time of admission were divided into 3 groups: 36 patients who continued ALF (ALF-C), 12 who were switched to ELD (ELD-S), and 19 who discontinued VDRAs (DC). The changes in weekly serum Ca levels and renal function during hospitalization were compared between the groups. At the second week of observation, the change in the serum Ca level was 0.01 mg/dL in the ALF-C group, +0.45 mg/dL in the ELD-S group, and -0.37 mg/dL in the DC group, showing a significant difference among these groups. In addition, serum Ca levels were increased in all patients in the ELD-S group at Week 2. The estimated glomerular filtration rate didn't change significantly in any group during hospitalization. These results suggest that serum Ca levels should be measured by Week 2 when ELD is newly started or changed.

活性维生素D3 (VDRAs)可引起药物性高钙血症和急性肾功能衰竭。Eldecalcitol (ELD),一种VDRA,比其他VDRA如alfacalcidol (ALF)更强烈地促进骨形成,但ELD是否比其他VDRA更显著地影响血清钙水平和肾功能尚不清楚。在日本,2021年暂时停止了ALF的供应,福冈大学医院服用ALF的患者要么改用ELD,要么停止使用ALF。我们回顾性地研究了这些处方变化如何影响血清钙水平和肾功能。我们将在2021年9月至2022年3月期间在我院住院至少5天且入院时正在服用ALF的67名成年患者分为3组:36名患者继续使用ALF (ALF- c), 12名患者改用ELD (ELD- s), 19名患者停用VDRAs (DC)。比较两组住院期间周血钙水平及肾功能的变化。观察第2周时,ALF-C组血钙水平变化为0.01 mg/dL, ELD-S组血钙水平变化为+0.45 mg/dL, DC组血钙水平变化为-0.37 mg/dL,组间差异有统计学意义。此外,在第2周,所有ELD-S组患者的血清钙水平均升高。两组患者住院期间肾小球滤过率均无明显变化。这些结果表明,血清钙水平应在第2周ELD刚开始或改变时测量。
{"title":"[Changes in the Serum Calcium Level and Renal Function After Switching from Alfacalcidol to Eldecalcitol].","authors":"Hiroko Nagae, Haruka Nagai-Nakamura, Kouhei Noda, Daiki Hagiwara, Susumu Kaneshige, Hidetoshi Kamimura","doi":"10.1248/yakushi.24-00160","DOIUrl":"10.1248/yakushi.24-00160","url":null,"abstract":"<p><p>Active vitamin D<sub>3</sub> (VDRAs) can cause drug-induced hypercalcemia and acute renal failure. Eldecalcitol (ELD), a VDRA, promotes bone formation more strongly than other VDRAs, such as alfacalcidol (ALF), but whether or not ELD affects serum calcium (Ca) levels and renal function more significantly than other VDRAs is unclear. In Japan, the supply of ALF was temporarily stopped in 2021, and patients at Fukuoka University Hospital who were taking ALF were either switched to ELD or discontinued ALF. We retrospectively investigated how these prescription changes affected serum Ca levels and renal function. Sixty-seven adult patients who were admitted to our hospital for at least 5 d between September 2021 and March 2022 and were taking ALF at the time of admission were divided into 3 groups: 36 patients who continued ALF (ALF-C), 12 who were switched to ELD (ELD-S), and 19 who discontinued VDRAs (DC). The changes in weekly serum Ca levels and renal function during hospitalization were compared between the groups. At the second week of observation, the change in the serum Ca level was 0.01 mg/dL in the ALF-C group, +0.45 mg/dL in the ELD-S group, and -0.37 mg/dL in the DC group, showing a significant difference among these groups. In addition, serum Ca levels were increased in all patients in the ELD-S group at Week 2. The estimated glomerular filtration rate didn't change significantly in any group during hospitalization. These results suggest that serum Ca levels should be measured by Week 2 when ELD is newly started or changed.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":" ","pages":"351-357"},"PeriodicalIF":0.3,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143256434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Survey on the Current Status of Initial Pharmacist Interviews among Patients Receiving Surgery during the Weekday Day Shift]. [平日白班期间接受手术的患者初次药剂师访谈现状调查]。
IF 0.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-02-01 Epub Date: 2024-11-26 DOI: 10.1248/yakushi.23-00203
Yasuhiro Saito, Kota Horii, Keiji Yagisawa, Akira Tokutome, Satoshi Gando, Takayuki Kimyo

Comprehensive exploratory surveys of pharmacist involvement with perioperative patients were conducted to identify the current issues and challenges. In the first survey, patients who underwent surgery under general anesthesia during the weekday day shift at Sapporo Higashi Tokushukai Hospital between April 1 and September 30, 2022, were included. Patient backgrounds, surgery-related information, and initial preoperative pharmacist interviews were investigated. In the second survey, the questionnaire was administered to anesthesiologists and operating room nurses at our hospital between March 1 and March 31, 2023. Of the patients who underwent surgery during the weekday day shift, the initial preoperative pharmacist interview was not conducted for approximately 1 in 10 cases. Patients who were not interviewed were more likely to be hospitalized on weekends, holidays, or at night and were more commonly trauma patients. Both anesthesiologists and operating room nurses indicated that the work of operating room pharmacists "supported their work," "improved the quality of care," and "improved medical safety."

我们对药剂师参与围手术期患者治疗的情况进行了全面的探索性调查,以找出当前存在的问题和面临的挑战。第一次调查的对象包括 2022 年 4 月 1 日至 9 月 30 日期间在札幌东德洲会医院工作日白班接受全身麻醉手术的患者。调查内容包括患者背景、手术相关信息以及术前药剂师的初步访谈。在第二次调查中,我们在 2023 年 3 月 1 日至 3 月 31 日期间对本院的麻醉师和手术室护士进行了问卷调查。在工作日白班期间接受手术的患者中,约有十分之一的患者未进行术前药剂师初次访谈。未接受访谈的患者更有可能在周末、节假日或夜间住院,而且更常见的是外伤患者。麻醉师和手术室护士都表示,手术室药剂师的工作 "支持了他们的工作"、"提高了护理质量 "和 "改善了医疗安全"。
{"title":"[Survey on the Current Status of Initial Pharmacist Interviews among Patients Receiving Surgery during the Weekday Day Shift].","authors":"Yasuhiro Saito, Kota Horii, Keiji Yagisawa, Akira Tokutome, Satoshi Gando, Takayuki Kimyo","doi":"10.1248/yakushi.23-00203","DOIUrl":"10.1248/yakushi.23-00203","url":null,"abstract":"<p><p>Comprehensive exploratory surveys of pharmacist involvement with perioperative patients were conducted to identify the current issues and challenges. In the first survey, patients who underwent surgery under general anesthesia during the weekday day shift at Sapporo Higashi Tokushukai Hospital between April 1 and September 30, 2022, were included. Patient backgrounds, surgery-related information, and initial preoperative pharmacist interviews were investigated. In the second survey, the questionnaire was administered to anesthesiologists and operating room nurses at our hospital between March 1 and March 31, 2023. Of the patients who underwent surgery during the weekday day shift, the initial preoperative pharmacist interview was not conducted for approximately 1 in 10 cases. Patients who were not interviewed were more likely to be hospitalized on weekends, holidays, or at night and were more commonly trauma patients. Both anesthesiologists and operating room nurses indicated that the work of operating room pharmacists \"supported their work,\" \"improved the quality of care,\" and \"improved medical safety.\"</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":" ","pages":"145-154"},"PeriodicalIF":0.3,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142740157","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Development of Intraoperative Near-infrared Fluorescent Ureteral Imaging Agent to Prevent Iatrogenic Ureteral Injury]. 术中近红外输尿管荧光显像剂预防医源性输尿管损伤的研制
IF 0.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.1248/yakushi.24-00205
Katsunori Teranishi

The adult ureter is a delicate structure with an approximate internal diameter of 5 mm located deep within the lower abdomen and surrounded by various tissues. Therefore, due to its positioning, visual identification of the ureter is challenging. Iatrogenic ureteral injuries, which can lead to severe illness, occur during both open and laparoscopic abdominal surgeries, posing a serious clinical concern. Reliable intraoperative identification of the ureters is essential to prevent inadvertent injuries. Ureteral stenting or catheter placement, commonly used procedure for ureteral identification, involve insertion via the urethra and bladder. However, these techniques have limitations, including prolonged surgery time, risk of urinary tract complications, limited diagnostic capability for ureteral injury, and higher medical costs. Optical imaging has the potential to assist in surgeries involving invisible tissues. Recently, novel fluorescent compounds, ASP5354, ZW800-1, and IS-001, has entered phase 3 clinical trials for intravenous use in intraoperative ureteral identification and injury diagnosis. These compounds possess a heptamethine cyanine skeleton that generates near-infrared fluorescence (700-900 nm), exhibit excellent tissue permeability, enable ureteral visualization throughout minimally invasive laparoscopic procedures, and are safe and well tolerated. Notably, no adverse events have been reported in clinical trials to date. This review provides an overview of these promising compounds and their potential effect in improving surgical outcomes.

成人输尿管是一个微妙的结构,内径约为5mm,位于下腹深处,被各种组织包围。因此,由于其位置,输尿管的视觉识别是具有挑战性的。医源性输尿管损伤可导致严重疾病,发生在开放和腹腔镜腹部手术中,引起严重的临床关注。术中可靠的输尿管识别对于防止意外损伤至关重要。输尿管支架置入术或导尿管置入术是输尿管识别的常用方法,涉及经尿道和膀胱插入。然而,这些技术有局限性,包括手术时间延长、尿路并发症的风险、输尿管损伤的诊断能力有限以及较高的医疗费用。光学成像有可能在涉及不可见组织的手术中提供帮助。最近,新型荧光化合物ASP5354、ZW800-1和IS-001已进入3期临床试验,用于静脉输尿管术中识别和损伤诊断。这些化合物具有能产生近红外荧光(700-900 nm)的七甲基菁氨酸骨架,具有优异的组织渗透性,在微创腹腔镜手术过程中实现输尿管可视化,并且安全且耐受性良好。值得注意的是,迄今为止在临床试验中未报告任何不良事件。本文综述了这些有前途的化合物及其在改善手术结果方面的潜在作用。
{"title":"[Development of Intraoperative Near-infrared Fluorescent Ureteral Imaging Agent to Prevent Iatrogenic Ureteral Injury].","authors":"Katsunori Teranishi","doi":"10.1248/yakushi.24-00205","DOIUrl":"https://doi.org/10.1248/yakushi.24-00205","url":null,"abstract":"<p><p>The adult ureter is a delicate structure with an approximate internal diameter of 5 mm located deep within the lower abdomen and surrounded by various tissues. Therefore, due to its positioning, visual identification of the ureter is challenging. Iatrogenic ureteral injuries, which can lead to severe illness, occur during both open and laparoscopic abdominal surgeries, posing a serious clinical concern. Reliable intraoperative identification of the ureters is essential to prevent inadvertent injuries. Ureteral stenting or catheter placement, commonly used procedure for ureteral identification, involve insertion via the urethra and bladder. However, these techniques have limitations, including prolonged surgery time, risk of urinary tract complications, limited diagnostic capability for ureteral injury, and higher medical costs. Optical imaging has the potential to assist in surgeries involving invisible tissues. Recently, novel fluorescent compounds, ASP5354, ZW800-1, and IS-001, has entered phase 3 clinical trials for intravenous use in intraoperative ureteral identification and injury diagnosis. These compounds possess a heptamethine cyanine skeleton that generates near-infrared fluorescence (700-900 nm), exhibit excellent tissue permeability, enable ureteral visualization throughout minimally invasive laparoscopic procedures, and are safe and well tolerated. Notably, no adverse events have been reported in clinical trials to date. This review provides an overview of these promising compounds and their potential effect in improving surgical outcomes.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"145 5","pages":"451-459"},"PeriodicalIF":0.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143988984","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Setting of Maximum Residue Limits (MRLs) for Pesticides in Foods]. [设定食物中农药的最高残留限量]。
IF 0.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.1248/yakushi.24-00164-1
Rie Tanaka

Under the Food Sanitation Law, standards for the production and specifications of food ingredients for distribution may be established. Food that does not meet these standards is prohibited from being distributed. For pesticide residues in food, maximum residue limits (MRLs) are set for each pesticide and food type. Even pesticides without specific MRLs must comply with a uniform limit of 0.01 ppm. Thus, the positive list system controls pesticide residues in food in Japan. The MRLs for the pesticides were established based on current international agreements and concepts, and are calculated from crop residue trials for registered usage methods where maximum residue concentrations are expected. MRLs are determined if the dietary intake, when draft MRLs are adopted, does not exceed the acceptable daily intake (ADI) and acute reference dose (ARfD) as evaluated by the Food Safety Commission. The residue definition for MRL setting may be selected from the pesticide components themselves but also their metabolites and degradates, determined by considering the feasibility of analytical methods. Exposure to pesticides via food is estimated using monitoring data from quarantine stations and local governments, as well as market basket surveys. Currently, this exposure level is considered tolerable.

依照《食品卫生法》的规定,可以制定食品配料的生产标准和经营规范。不符合这些标准的食品是禁止销售的。对于食品中的农药残留,每种农药和食品都设定了最大残留限量(MRLs)。即使没有特定最大残留限量的农药也必须遵守0.01 ppm的统一限值。因此,正面清单制度在日本控制食品中的农药残留。农药的最大残留限量是根据目前的国际协议和概念确定的,并根据预计最大残留浓度的注册使用方法的作物残留试验计算得出。当最大限量草案通过时,如果膳食摄入量不超过食品安全委员会评估的可接受每日摄入量(ADI)和急性参考剂量(ARfD),则确定最大限量。MRL设置的残留定义可以从农药成分本身选择,也可以从其代谢物和降解物中选择,并考虑分析方法的可行性来确定。通过食品接触农药的情况是根据检疫站和地方政府的监测数据以及市场篮子调查来估计的。目前,这种暴露水平被认为是可以容忍的。
{"title":"[Setting of Maximum Residue Limits (MRLs) for Pesticides in Foods].","authors":"Rie Tanaka","doi":"10.1248/yakushi.24-00164-1","DOIUrl":"10.1248/yakushi.24-00164-1","url":null,"abstract":"<p><p>Under the Food Sanitation Law, standards for the production and specifications of food ingredients for distribution may be established. Food that does not meet these standards is prohibited from being distributed. For pesticide residues in food, maximum residue limits (MRLs) are set for each pesticide and food type. Even pesticides without specific MRLs must comply with a uniform limit of 0.01 ppm. Thus, the positive list system controls pesticide residues in food in Japan. The MRLs for the pesticides were established based on current international agreements and concepts, and are calculated from crop residue trials for registered usage methods where maximum residue concentrations are expected. MRLs are determined if the dietary intake, when draft MRLs are adopted, does not exceed the acceptable daily intake (ADI) and acute reference dose (ARfD) as evaluated by the Food Safety Commission. The residue definition for MRL setting may be selected from the pesticide components themselves but also their metabolites and degradates, determined by considering the feasibility of analytical methods. Exposure to pesticides via food is estimated using monitoring data from quarantine stations and local governments, as well as market basket surveys. Currently, this exposure level is considered tolerable.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"145 2","pages":"95-99"},"PeriodicalIF":0.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143081254","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Essential Components of Pharmacist-Prepared Home Care Reports to Facilitate Information Sharing from the Pharmacy Pharmacist to Other Professionals]. [药剂师编写家庭护理报告的基本要素,以促进药剂师与其他专业人员共享信息]。
IF 0.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.1248/yakushi.24-00102
Anna Yokoi, Eisei Hori, Chihiro Yoshinaga, Suzuka Mii, Masako Mizuno, Noriko Mizuno, Haruyuki Asai, Yoko Yamada, Hiroki Miyake, Tomoyasu Ishikawa, Masashi Tomoda, Chigusa Kikuchi, Tadashi Suzuki

In this study, we assessed the information sharing practices between pharmacists and multidisciplinary healthcare professionals such as doctors, care managers, and nurses, and others. We evaluated the effectiveness of "home medical care management guidance reports" and "home-visit drug management guidance reports" prepared by pharmacists. We also identified factors that could enhance collaborative practices. To improve the reports, we introduced a new report form with an overview column and a reply column. We used the SOAP format in the new reports. We found that the response rate for reports from X pharmacy was significantly higher than that of Y pharmacies. A survey revealed that X's reports contained more categories (median of 3 versus 1 in Y's reports). Pharmacy X's reports had a smaller proportion of pharmacotherapy details, and a larger proportion of information regarding patients' living and health conditions, as well as environmental factors. We also found that the character count in X's assessment column was significantly greater (168.5 versus 60), and notably less in the overview sections (12 versus 22) when compared to Y's reports. Suggestions and guidance constituted a significantly larger portion of X's reports (29.8% compared to 10.8% in Y's). Questionnaire feedback from other healthcare professionals to whom the subject pharmacies send reports highlighted the importance of pharmacist-provided information on health and living conditions, based on pharmacological knowledge. Based on these results, to enhance health information sharing, pharmacists should integrate assessments of pharmacotherapy with health and living conditions and effectively communicate this information to other professionals.

在这项研究中,我们评估了药剂师和多学科医疗保健专业人员(如医生、护理经理、护士和其他人)之间的信息共享实践。对药师编制的《居家医疗管理指导报告》和《家访药品管理指导报告》的有效性进行评价。我们还确定了可以增强协作实践的因素。为了改进报表,我们引入了一个包含概述列和回复列的新报表表单。我们在新的报告中使用SOAP格式。我们发现X药房的报告回复率明显高于Y药房。一项调查显示,X的报告包含更多的类别(中位数为3,而Y的报告为1)。药房X的报告中药物治疗细节的比例较小,关于患者生活和健康状况以及环境因素的信息比例较大。我们还发现,与Y的报告相比,X的评估列中的字符数显著增加(168.5对60),而概述部分的字符数明显减少(12对22)。建议和指导在X的报告中所占的比例要大得多(29.8%,Y的报告为10.8%)。主题药房向其发送报告的其他保健专业人员的问卷反馈强调了药剂师根据药理学知识提供的关于健康和生活条件的信息的重要性。基于这些结果,药师应将药物治疗评估与健康和生活状况结合起来,并有效地与其他专业人员沟通,以加强健康信息共享。
{"title":"[Essential Components of Pharmacist-Prepared Home Care Reports to Facilitate Information Sharing from the Pharmacy Pharmacist to Other Professionals].","authors":"Anna Yokoi, Eisei Hori, Chihiro Yoshinaga, Suzuka Mii, Masako Mizuno, Noriko Mizuno, Haruyuki Asai, Yoko Yamada, Hiroki Miyake, Tomoyasu Ishikawa, Masashi Tomoda, Chigusa Kikuchi, Tadashi Suzuki","doi":"10.1248/yakushi.24-00102","DOIUrl":"10.1248/yakushi.24-00102","url":null,"abstract":"<p><p>In this study, we assessed the information sharing practices between pharmacists and multidisciplinary healthcare professionals such as doctors, care managers, and nurses, and others. We evaluated the effectiveness of \"home medical care management guidance reports\" and \"home-visit drug management guidance reports\" prepared by pharmacists. We also identified factors that could enhance collaborative practices. To improve the reports, we introduced a new report form with an overview column and a reply column. We used the SOAP format in the new reports. We found that the response rate for reports from X pharmacy was significantly higher than that of Y pharmacies. A survey revealed that X's reports contained more categories (median of 3 versus 1 in Y's reports). Pharmacy X's reports had a smaller proportion of pharmacotherapy details, and a larger proportion of information regarding patients' living and health conditions, as well as environmental factors. We also found that the character count in X's assessment column was significantly greater (168.5 versus 60), and notably less in the overview sections (12 versus 22) when compared to Y's reports. Suggestions and guidance constituted a significantly larger portion of X's reports (29.8% compared to 10.8% in Y's). Questionnaire feedback from other healthcare professionals to whom the subject pharmacies send reports highlighted the importance of pharmacist-provided information on health and living conditions, based on pharmacological knowledge. Based on these results, to enhance health information sharing, pharmacists should integrate assessments of pharmacotherapy with health and living conditions and effectively communicate this information to other professionals.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"145 3","pages":"247-256"},"PeriodicalIF":0.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143537912","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
[Fetal Heart Failure: Exploring Diagnosis and Treatment Strategies]. [胎儿心力衰竭:诊断和治疗策略的探索]。
IF 0.3 4区 医学 Q4 PHARMACOLOGY & PHARMACY Pub Date : 2025-01-01 DOI: 10.1248/yakushi.24-00171-2
Hiroshi Hosoda

It is difficult to appropriately diagnose the severity of fetal heart failure using only ultrasonography. Biomarkers of fetal heart failure in the fetal blood, amniotic fluid, and maternal blood have not been established. Therefore, we investigated natriuretic peptides (NPs) such as Atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and N-terminal proBNP (NT-proBNP) in umbilical cord blood and amniotic fluid in cases of fetuses with congenital heart disease, and investigated whether maternal serum biomarkers could diagnose fetal heart failure. The features of NPs in the umbilical cord blood and amniotic fluid provide a strong basis for their use as biomarkers of fetal heart failure. Maternal serum concentrations of tumor necrosis factor (TNF-α), vascular endothelial growth factor-D (VEGF-D), and heparin-binding epidermal growth factor-like growth factor (HB-EGF) can be used to assess fetal heart failure severity. There are no established transplacental treatments for heart failure in utero, and no animal models or experimental systems of fetal heart failure have been established. We first used an ultra-high-frequency ultrasound imaging system in utero and demonstrated that Hrt2 knockout (KO) embryos had marked left ventricular (LV) dilatation as well as worsening fractional shortening (FS) as gestation progressed, indicating that the embryos can be used as a murine model of fetal heart failure. Subsequently, we evaluated the effect of tadalafil treatment on fetoplacental circulation in Hrt2 KO embryos. LV FS was significantly higher in the tadalafil group than in the control group. Maternal administration of tadalafil improved LV systolic function without altering LV morphological abnormalities in Hrt2 KO embryos. Our findings suggest that tadalafil may effectively treat impaired fetal ventricular systolic function.

仅通过超声检查很难正确诊断胎儿心力衰竭的严重程度。胎儿血液、羊水和母体血液中胎儿心力衰竭的生物标志物尚未确定。因此,我们研究了先天性心脏病胎儿脐带血和羊水中心房钠肽(ANP)、脑钠肽(BNP)和n端proBNP (NT-proBNP)等钠肽(NPs),并探讨了母体血清生物标志物是否可以诊断胎儿心力衰竭。脐带血和羊水中NPs的特征为其作为胎儿心力衰竭的生物标志物提供了强有力的基础。孕妇血清肿瘤坏死因子(TNF-α)、血管内皮生长因子- d (VEGF-D)和肝素结合表皮生长因子样生长因子(HB-EGF)浓度可用于评估胎儿心力衰竭的严重程度。子宫内心力衰竭的经胎盘治疗尚无定论,胎儿心力衰竭的动物模型或实验系统也尚未建立。我们首先在子宫内使用超高频超声成像系统,并证明Hrt2基因敲除(KO)胚胎随着妊娠的进展,左心室(LV)扩张和分数缩短(FS)恶化,表明胚胎可以用作胎儿心力衰竭的小鼠模型。随后,我们评估了他达拉非治疗对Hrt2 KO胚胎胎胎盘循环的影响。他达拉非组lvfs明显高于对照组。母体给予他达拉非可改善Hrt2 KO胚胎左室收缩功能,但未改变左室形态异常。我们的研究结果表明,他达拉非可以有效地治疗胎儿心室收缩功能受损。
{"title":"[Fetal Heart Failure: Exploring Diagnosis and Treatment Strategies].","authors":"Hiroshi Hosoda","doi":"10.1248/yakushi.24-00171-2","DOIUrl":"10.1248/yakushi.24-00171-2","url":null,"abstract":"<p><p>It is difficult to appropriately diagnose the severity of fetal heart failure using only ultrasonography. Biomarkers of fetal heart failure in the fetal blood, amniotic fluid, and maternal blood have not been established. Therefore, we investigated natriuretic peptides (NPs) such as Atrial natriuretic peptide (ANP), brain natriuretic peptide (BNP), and N-terminal proBNP (NT-proBNP) in umbilical cord blood and amniotic fluid in cases of fetuses with congenital heart disease, and investigated whether maternal serum biomarkers could diagnose fetal heart failure. The features of NPs in the umbilical cord blood and amniotic fluid provide a strong basis for their use as biomarkers of fetal heart failure. Maternal serum concentrations of tumor necrosis factor (TNF-α), vascular endothelial growth factor-D (VEGF-D), and heparin-binding epidermal growth factor-like growth factor (HB-EGF) can be used to assess fetal heart failure severity. There are no established transplacental treatments for heart failure in utero, and no animal models or experimental systems of fetal heart failure have been established. We first used an ultra-high-frequency ultrasound imaging system in utero and demonstrated that Hrt2 knockout (KO) embryos had marked left ventricular (LV) dilatation as well as worsening fractional shortening (FS) as gestation progressed, indicating that the embryos can be used as a murine model of fetal heart failure. Subsequently, we evaluated the effect of tadalafil treatment on fetoplacental circulation in Hrt2 KO embryos. LV FS was significantly higher in the tadalafil group than in the control group. Maternal administration of tadalafil improved LV systolic function without altering LV morphological abnormalities in Hrt2 KO embryos. Our findings suggest that tadalafil may effectively treat impaired fetal ventricular systolic function.</p>","PeriodicalId":23810,"journal":{"name":"Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan","volume":"145 4","pages":"281-288"},"PeriodicalIF":0.3,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143773447","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1